Hudson M M, Donaldson S S
Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Pediatr Clin North Am. 1997 Aug;44(4):891-906. doi: 10.1016/s0031-3955(05)70535-6.
Despite incomplete understanding of the etiology of Hodgkin's disease and its malignant cell of origin, the majority of children and adolescents diagnosed with Hodgkin's disease will be longterm survivors. Staging and treatment for pediatric Hodgkin's disease has evolved over the past 30 years in attempts to reduce late treatment sequelae. Today, most children are clinically staged and treated with multitreatment chemotherapy, either alone or in conjunction with low-dose, involved field radiation therapy. Initial results with "risk-adapted" combined modality regimens limiting chemotherapy cycles and radiation doses and volumes demonstrate maintenance of cure rates for early stage, favorable Hodgkin's disease. Challenges for the future include identification of prognostic factors in patients at risk for treatment failure who may benefit from intensification of therapy.
尽管对霍奇金淋巴瘤的病因及其恶性起源细胞尚未完全了解，但大多数被诊断为霍奇金淋巴瘤的儿童和青少年将成为长期幸存者。在过去30年中，小儿霍奇金淋巴瘤的分期和治疗方法不断演变，旨在减少晚期治疗后遗症。如今，大多数儿童通过多疗程化疗进行临床分期和治疗，化疗可单独使用，也可与低剂量受累野放射治疗联合使用。采用“风险适应性”联合治疗方案，限制化疗周期以及放射剂量和范围，早期、预后良好的霍奇金淋巴瘤的治愈率得以维持。未来的挑战包括确定那些有治疗失败风险、可能从强化治疗中获益的患者的预后因素。
